scAAV9 CLN3 (ABO-201)

Collapse Summary General Information
Company Abeona Therapeutics Inc.
DescriptionAdeno-associated viral serotype 9 (AAV9) vector that delivers the ceroid-lipofuscinosis neuronal 3 (CLN3) gene
Molecular Target Ceroid-lipofuscinosis neuronal 3 (CLN3)
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard Indication Neurology (unspecified)
Indication DetailsTreat juvenile Batten disease
Regulatory Designation EU - Orphan Drug (Treat juvenile Batten disease)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/08/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today